SOX2 and non-small cell lung carcinoma: In support of this, several meta-analyses have shown that SOX2 expression in non–small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma (ESCC) correlates with better survival outcomes [49,50,51].